Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Blade
South San Francisco, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Blade Therapeutics is advancing a pipeline of oral, small-molecule therapies for fibrotic and neurodegenerative diseases. Cudetaxestat, a non-competitive autotaxin inhibitor, is planned for a Phase 2 study in idiopathic pulmonary fibrosis, while BLD-2184 is a CNS-penetrant calpain inhibitor for neurodegenerative conditions[2][3].
- Therapeutic areas
- CardiovascularGastroenterologyPulmonologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Biotech Acquisition Company (BAC)SPRIM Global InvestmentsDeerfield ManagementPfizer VenturesBristol Myers SquibbMPM CapitalOsage University Partners
Beyond the preview
Go deeper on Blade.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Blade.